mRNA vaccine

Extended-protected article
Source: Wikipedia, the free encyclopedia.
(Redirected from
RNA vaccine
)

mRNA in vitro transcription, innate and adaptive immunity activation

An mRNA vaccine is a type of

lipid nanoparticles that protect the RNA strands and help their absorption into the cells.[2][3]

Video showing how vaccination with an mRNA vaccine works

cellular and humoral immunity, and lack of interaction with the genomic DNA.[5][6] While some messenger RNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine, have the disadvantage of requiring ultracold storage before distribution,[1] other mRNA vaccines, such as the Moderna, CureVac, and Walvax COVID-19 vaccines, do not have such requirements.[7][8]

In RNA therapeutics, messenger RNA vaccines have attracted considerable interest as COVID-19 vaccines.[1] In December 2020, Pfizer–BioNTech and Moderna obtained authorization for their mRNA-based COVID-19 vaccines. On 2 December, the UK Medicines and Healthcare products Regulatory Agency (MHRA) became the first medicines regulator to approve an mRNA vaccine, authorizing the Pfizer–BioNTech vaccine for widespread use.[9][10][11] On 11 December, the US Food and Drug Administration (FDA) issued an emergency use authorization for the Pfizer–BioNTech vaccine[12][13] and a week later similarly authorized the Moderna vaccine.[14][15]

History

Early research

Timeline of some key discoveries and advances in the development of mRNA-based drug technology.

The first successful transfection of designed mRNA packaged within a liposomal nanoparticle into a cell was published in 1989.[16][17] "Naked" (or unprotected) lab-made mRNA was injected a year later into the muscle of mice.[3][18] These studies were the first evidence that in vitro transcribed mRNA with a chosen gene was able to deliver the genetic information to produce a desired protein within living cell tissue[3] and led to the concept proposal of messenger RNA vaccines.[19][20][21]

Liposome-encapsulated mRNA encoding a viral antigen was shown in 1993 to stimulate T cells in mice.[22][23] The following year self-amplifying mRNA was developed by including both a viral antigen and replicase encoding gene.[22][24] The method was used in mice to elicit both a humoral and cellular immune response against a viral pathogen.[22] The next year mRNA encoding a tumor antigen was shown to elicit a similar immune response against cancer cells in mice.[25][26]

Development

The first human clinical trial using

mRNA vaccine directly injected into the body against cancer cells were reported in 2008.[30][31]

BioNTech in 2008, and Moderna in 2010, were founded to develop mRNA biotechnologies.[32][33] The US research agency DARPA launched at this time the biotechnology research program ADEPT to develop emerging technologies for the US military.[34][35] The agency recognized the potential of nucleic acid technology for defense against pandemics and began to invest in the field.[34] DARPA grants were seen as a vote of confidence that in turn encouraged other government agencies and private investors to invest in mRNA technology.[35] DARPA awarded at the time a $25 million grant to Moderna.[36]

The first human clinical trials using an mRNA vaccine against an infectious agent (

Chikungunya virus.[40][41]

In March 2022

Middle East respiratory syndrome coronavirus (MERS-CoV), Nipah and henipaviral diseases, Rift Valley fever, Severe fever with Thrombocytopenia syndrome, Tuberculosis and Zika.[42][43]

Acceleration

The

FDA gave emergency use authorization for the Pfizer–BioNTech COVID-19 vaccine and a week later similar approval for the Moderna COVID-19 vaccine.[47]
Other mRNA vaccines continued under development.

Mechanism

Further information: Immune system
An illustration of the mechanism of action of a messenger RNA vaccine

The goal of a vaccine is to stimulate the adaptive immune system to create antibodies that precisely target that particular pathogen. The markers on the pathogen that the antibodies target are called antigens.[48]

Traditional vaccines stimulate an antibody response by injecting either

attenuated (weakened) virus, an inactivated (dead) virus, or a recombinant antigen-encoding viral vector (harmless carrier virus with an antigen transgene) into the body. These antigens and viruses are prepared and grown outside the body.[49][50]

In contrast, mRNA vaccines introduce a short-lived[51] synthetically created fragment of the RNA sequence of a virus into the individual being vaccinated. These mRNA fragments are taken up by dendritic cells through phagocytosis.[52] The dendritic cells use their internal machinery (ribosomes) to read the mRNA and produce the viral antigens that the mRNA encodes.[4] The body degrades the mRNA fragments within a few days of introduction.[53] Although non-immune cells can potentially also absorb vaccine mRNA, produce antigens, and display the antigens on their surfaces, dendritic cells absorb the mRNA globules much more readily.[54] The mRNA fragments are translated in the cytoplasm and do not affect the body's genomic DNA, located separately in the cell nucleus.[1][55]

Once the viral antigens are produced by the host cell, the normal adaptive immune system processes are followed. Antigens are broken down by

immunity.[48]

mRNA

mRNA components important for expressing the antigen sequence

The central component of a mRNA vaccine is its mRNA construct.[57] The in vitro transcribed mRNA is generated from an engineered plasmid DNA, which has an RNA polymerase promoter and sequence which corresponds to the mRNA construct. By combining T7 phage RNA polymerase and the plasmid DNA, the mRNA can be transcribed in the lab. Efficacy of the vaccine is dependent on the stability and structure of the designed mRNA.[4]

The in vitro transcribed mRNA has the same structural components as natural mRNA in

3'-poly(A) tail. By modifying these different components of the synthetic mRNA, the stability and translational ability of the mRNA can be enhanced, and in turn, the efficacy of the vaccine improved.[57]

The mRNA can be improved by using synthetic 5'-cap analogues which enhance the stability and increase protein translation. Similarly,

codons with synonymous codons frequently used by the host cell also enhances protein production.[4]

Delivery

Major delivery methods and carrier molecules for mRNA vaccines

For a vaccine to be successful, sufficient mRNA must enter the host cell cytoplasm to stimulate production of the specific antigens. Entry of mRNA molecules, however, faces a number of difficulties. Not only are mRNA molecules too large to cross the cell membrane by simple diffusion, they are also negatively charged like the cell membrane, which causes a mutual electrostatic repulsion. Additionally, mRNA is easily degraded by RNAases in skin and blood.[55]

Various methods have been developed to overcome these delivery hurdles. The method of vaccine delivery can be broadly classified by whether mRNA transfer into cells occurs within (in vivo) or outside (ex vivo) the organism.[55][3]

Ex vivo

surfaces, leading to interactions with T cells to initiate an immune response. Dendritic cells can be collected from patients and programmed with the desired mRNA, then administered back into patients to create an immune response.[58]

The simplest way that ex vivo dendritic cells take up mRNA molecules is through endocytosis, a fairly inefficient pathway in the laboratory setting that can be significantly improved through electroporation.[55]

In vivo

Since the discovery that the direct administration of in vitro transcribed mRNA leads to the expression of antigens in the body, in vivo approaches have been investigated.[18] They offer some advantages over ex vivo methods, particularly by avoiding the cost of harvesting and adapting dendritic cells from patients and by imitating a regular infection.[55]

Different routes of

muscles, result in varying levels of mRNA uptake, making the choice of administration route a critical aspect of in vivo delivery. One study showed, in comparing different routes, that lymph node injection leads to the largest T-cell response.[59]

Naked mRNA injection

Naked mRNA injection means that the delivery of the vaccine is only done in a buffer solution.[60] This mode of mRNA uptake has been known since the 1990s.[18] The first worldwide clinical studies used intradermal injections of naked mRNA for vaccination.[61][62] A variety of methods have been used to deliver naked mRNA, such as subcutaneous, intravenous, and intratumoral injections. Although naked mRNA delivery causes an immune response, the effect is relatively weak, and after injection the mRNA is often rapidly degraded.[55]

Polymer and peptide vectors

cationic peptide and has been used to encapsulate mRNA for vaccination.[63][non-primary source needed][64]

Lipid nanoparticle vector

Assembly of RNA lipid nanoparticle

The first time the FDA approved the use of

Onpattro.[65] Encapsulating the mRNA molecule in lipid nanoparticles was a critical breakthrough for producing viable mRNA vaccines, solving a number of key technical barriers in delivering the mRNA molecule into the host cell.[65][66] Research into using lipids to deliver siRNA to cells became a foundation for similar research into using lipids to deliver mRNA.[67] However, new lipids had to be invented to encapsulate mRNA strands, which are much longer than siRNA strands.[67]

Principally, the lipid provides a layer of protection against degradation, allowing more robust translational output. In addition, the customization of the lipid's outer layer allows the targeting of desired cell types through ligand interactions. However, many studies have also highlighted the difficulty of studying this type of delivery, demonstrating that there is an inconsistency between in vivo and in vitro applications of nanoparticles in terms of cellular intake.[68] The nanoparticles can be administered to the body and transported via multiple routes, such as intravenously or through the lymphatic system.[65]

One issue with lipid nanoparticles is that several of the breakthroughs leading to the practical use of that technology involve the use of

microfluidics. Microfluidic reaction chambers are difficult to scale up, since the entire point of microfluidics is to exploit the microscale behaviors of liquids. The only way around this obstacle is to run an extensive number of microfluidic reaction chambers in parallel, a novel task requiring custom-built equipment.[69][70] For COVID-19 mRNA vaccines, this was the main manufacturing bottleneck. Pfizer used such a parallel approach to solve the scaling problem. After verifying that impingement jet mixers could not be directly scaled up,[71] Pfizer made about 100 of the little mixers (each about the size of a U.S. half-dollar coin), connected them together with pumps and filters with a "maze of piping,"[72][73] and set up a computer system to regulate flow and pressure through the mixers.[71]

Another issue, with the large-scale use of this delivery method, is the availability of the novel lipids used to create lipid nanoparticles, especially ionizable cationic lipids. Before 2020, such lipids were manufactured in small quantities measured in grams or kilograms, and they were used for medical research and a handful of drugs for rare conditions. As the safety and efficacy of mRNA vaccines became clear in 2020, the few companies able to manufacture the requisite lipids were confronted with the challenge of scaling up production to respond to orders for several tons of lipids.[70][74]

Viral vector

Further information: Viral vector vaccine

In addition to non-viral delivery methods, RNA viruses have been engineered to achieve similar immunological responses. Typical RNA viruses used as vectors include retroviruses, lentiviruses, alphaviruses and rhabdoviruses, each of which can differ in structure and function.[75] Clinical studies have utilized such viruses on a range of diseases in model animals such as mice, chicken and primates.[76][77][78]

Advantages

Traditional vaccines

Advantages and disadvantages of different types of vaccine platforms

mRNA vaccines offer specific advantages over traditional

cellular immunity, as well as humoral immunity.[6][79]

mRNA vaccines have the production advantage that they can be designed swiftly. Moderna designed their

mRNA-1273 vaccine for COVID-19 in 2 days.[80] They can also be manufactured faster, more cheaply, and in a more standardized fashion (with fewer error rates in production), which can improve responsiveness to serious outbreaks.[4][5]

The Pfizer–BioNTech vaccine originally required 110 days to mass-produce (before Pfizer began to optimize the manufacturing process to only 60 days), which was substantially faster than traditional flu and polio vaccines.[72] Within that larger timeframe, the actual production time is only about 22 days: two weeks for molecular cloning of DNA plasmids and purification of DNA, four days for DNA-to-RNA transcription and purification of mRNA, and four days to encapsulate mRNA in lipid nanoparticles followed by fill and finish.[81] The majority of the days needed for each production run are allocated to rigorous quality control at each stage.[72]

DNA vaccines

In addition to sharing the advantages of theoretical

replication mechanism can be added to amplify antigen translation and therefore immune response, decreasing the amount of starting material needed.[84][85]

Disadvantages

Storage

Because mRNA is fragile, some vaccines must be kept at very low temperatures to avoid degrading and thus giving little effective immunity to the recipient. Pfizer–BioNTech's

mRNA-1273 vaccine can be stored between −25 and −15 °C (−13 and 5 °F),[88] which is comparable to a home freezer,[87] and that it remains stable between 2 and 8 °C (36 and 46 °F) for up to 30 days.[88][89] In November 2020, Nature reported, "While it's possible that differences in LNP formulations or mRNA secondary structures could account for the thermostability differences [between Moderna and BioNtech], many experts suspect both vaccine products will ultimately prove to have similar storage requirements and shelf lives under various temperature conditions."[79] Several platforms are being studied that may allow storage at higher temperatures.[4]

Recent

Before 2020, no mRNA technology platform (drug or vaccine) had been authorized for use in humans, so there was a risk of unknown effects.

emergency use authorization or expanded access authorization) after the eight-week period of post-final human trials.[90][91]

Side effects

Reactogenicity is similar to that of conventional, non-RNA vaccines. However, those susceptible to an autoimmune response may have an adverse reaction to mRNA vaccines.[4] The mRNA strands in the vaccine may elicit an unintended immune reaction – this entails the body believing itself to be sick, and the person feeling as if they are as a result. To minimize this, mRNA sequences in mRNA vaccines are designed to mimic those produced by host cells.[5]

Strong but transient reactogenic effects were reported in trials of novel COVID-19 mRNA vaccines; most people will not experience severe side effects which include fever and fatigue. Severe side effects are defined as those that prevent daily activity.[92]

Efficacy

The COVID-19 mRNA vaccines from Moderna and Pfizer–BioNTech have efficacy rates of 90 to 95 percent. Prior mRNA, drug trials on pathogens other than COVID-19 were not effective and had to be abandoned in the early phases of trials. The reason for the efficacy of the new mRNA vaccines is not clear.[93]

Physician-scientist Margaret Liu stated that the efficacy of the new COVID-19 mRNA vaccines could be due to the "sheer volume of resources" that went into development, or that the vaccines might be "triggering a nonspecific inflammatory response to the mRNA that could be heightening its specific immune response, given that the modified nucleoside technique reduced inflammation but hasn't eliminated it completely", and that "this may also explain the intense reactions such as aches and fevers reported in some recipients of the mRNA SARS-CoV-2 vaccines". These reactions though severe were transient and another view is that they were believed to be a reaction to the lipid drug delivery molecules.[93]

Hesitancy

Further information:
Misinformation related to the COVID-19 pandemic and vaccine hesitancy

There is misinformation implying that mRNA vaccines could alter DNA in the nucleus.

SARS-CoV-2 vaccines are single-stranded RNA) which enters the cell nucleus and uses reverse transcriptase to make DNA from the RNA in the cell nucleus. A retrovirus has mechanisms to be imported into the nucleus, but other mRNA (such as the vaccine) lack these mechanisms. Once inside the nucleus, creation of DNA from RNA cannot occur without a reverse transcriptase and appropriate primers, which both accompany a retrovirus, but which would not be present for other exogenous mRNA (such as a vaccine) even if it could enter the nucleus.[95]

Amplification

mRNA vaccines use either non-amplifying (conventional) mRNA or self-amplifying mRNA.[96] Pfizer–BioNTech and Moderna vaccines use non-amplifying mRNA. Both mRNA types continue to be investigated as vaccine methods against other potential pathogens and cancer.[30]

Non-amplifying

Mechanism of non-amplifying and self-amplifying mRNA vaccines

The initial mRNA vaccines use a non-amplifying mRNA construct.[64] Non-amplifying mRNA has only one open reading frame that codes for the antigen of interest.[96] The total amount of mRNA available to the cell is equal to the amount delivered by the vaccine. Dosage strength is limited by the amount of mRNA that can be delivered by the vaccine.[97] Non-amplifying vaccines replace uridine with N1-Methylpseudouridine in an attempt to reduce toxicity.[98]

Self-amplifying

Self-amplifying mRNA (saRNA) vaccines replicate their mRNA after transfection.[99] Self-amplifying mRNA has two open reading frames. The first frame, like conventional mRNA, codes for the antigen of interest. The second frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses.[99] The mechanisms and consequently the evaluation of self-amplifying mRNA may be different, as self-amplifying mRNA is a much bigger molecule.[3]

SaRNA vaccines being researched include a

SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants.[101][102] saRNA vaccines must use uridine, which is required for reproduction to occur.[98]

See also

References

  1. ^
    PMID 33340620
    .
  2. PMID 30846391
    .
  3. ^
    S2CID 202221207. Archived
    from the original on 11 January 2021. Retrieved 8 December 2020.
  4. ^
    PMID 29326426
    .
  5. ^ a b c d e PHG Foundation (2019). "RNA vaccines: an introduction". University of Cambridge. Archived from the original on 6 December 2018. Retrieved 18 November 2020.
  6. ^
    PMID 27987140
    .
  7. PMID 33321139
    .
  8. ^ "Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 May 2021. Archived from the original on 23 August 2021. Retrieved 19 August 2021.
  9. ^ a b "UK authorises Pfizer/BioNTech COVID-19 vaccine" (Press release). Department of Health and Social Care. 2 December 2020. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
  10. ^ a b Boseley S, Halliday J (2 December 2020). "UK approves Pfizer/BioNTech Covid vaccine for rollout next week". The Guardian. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
  11. ^ "Conditions of Authorisation for Pfizer/BioNTech COVID-19 Vaccine" (Decision). Medicines & Healthcare Products Regulatory Agency. 8 December 2020. Archived from the original on 7 December 2020. Retrieved 10 December 2020.
  12. ^ "FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 11 December 2020. Archived from the original on 31 January 2021. Retrieved 6 February 2021.
  13. PMID 33332292. Archived
    (PDF) from the original on 19 December 2020. Retrieved 7 February 2021.
  14. ^ "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). 18 December 2020. Archived from the original on 19 December 2020. Retrieved 21 December 2020.
  15. S2CID 229945697. Archived
    (PDF) from the original on 9 February 2021. Retrieved 7 February 2021.
  16. PMID 32916818
    . Initiation of cationic lipid-mediated mrna transfection; Concept proposal of mRNA-based drugs
  17. PMID 2762315
    .
  18. ^
    PMID 1690918
    .
  19. ^ May M (31 May 2021). "After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases". Nature. Archived from the original on 13 October 2021. Retrieved 31 July 2021. When the broad range of vaccines against COVID-19 were being tested in clinical trials, only a few experts expected the unproven technology of mRNA to be the star. Within 10 months, mRNA vaccines were both the first to be approved and the most effective. Although these are the first mRNA vaccines to be approved, the story of mRNA vaccines starts more than 30 years ago, with many bumps in the road along the way. In 1990, the late physician-scientist Jon Wolff and his University of Wisconsin colleagues injected mRNA into mice, which caused cells in the mice to produce the encoded proteins. In many ways, that work served as the first step toward making a vaccine from mRNA, but there was a long way to go—and there still is, for many applications.
  20. PMID 32916818
    . Concept proposal of mRNA vaccines (1990)
  21. ^ Patent: WO1990011092 Archived 14 October 2021 at the Wayback Machine; Inventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson; Assignees: Vical Inc., Wisconsin Alumni Research Foundation; Title: "Expression of Exogenous Polynucleotide Sequences in a Vertebrate Archived 9 December 2021 at the Wayback Machine"; (Quote: "The present invention relates to introduction of naked DNA and RNA sequences into a vertebrate to achieve controlled expression of a polypeptide. It is useful in gene therapy, vaccination, and any therapeutic situation in which a polypeptide should be administered to cells in vivo"; Example 8: mRNA vaccination of mice to produce the gpl20 protein of HIV virus); Priority date: 21 March 1989; Publication date: 4 October 1990.
  22. ^
    S2CID 19350848
    .
  23. S2CID 42640967
    .
  24. PMID 7879415
    .
  25. PMID 24757523
    .
  26. PMID 7882341
    .
  27. ^
    PMID 25233993
    .
  28. PMID 11828001
    .
  29. ^
    PMID 16111635
    .
  30. ^
    PMID 33525396
    .
  31. S2CID 8233422
    .
  32. ^ "BioNTech's founders: scientist couple in global spotlight". France 24. 13 November 2020. Archived from the original on 14 February 2021. Retrieved 31 July 2021.
  33. ^ Garade D (10 November 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. Archived from the original on 10 November 2020. Retrieved 16 November 2020.
  34. ^ a b Sonne P (30 July 2020). "How a secretive Pentagon agency seeded the ground for a rapid coronavirus cure". The Washington Post. Archived from the original on 2 August 2021. Retrieved 21 June 2021.
  35. ^ a b Usdin S (19 March 2020). "DARPA's gambles might have created the best hopes for stopping COVID-19". BioCentury. Archived from the original on 18 June 2021. Retrieved 19 June 2021.
  36. ^ "DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics" (Press release). 2 October 2013. Archived from the original on 2 June 2021. Retrieved 31 May 2021.
  37. S2CID 237515383
    .
  38. S2CID 7700297
    .
  39. S2CID 238637957
    .
  40. PMID 34394960
    .
  41. ^ "COVID-19 and Your Health". Centers for Disease Control and Prevention. 11 February 2020. Archived from the original on 3 March 2021. Retrieved 26 November 2020.
  42. ^ "Moderna Announces Its Global Public Health Strategy". investors.modernatx.com. Archived from the original on 16 March 2022. Retrieved 15 March 2022.
  43. ^ Steenhuysen, Julie; Erman, Michael (8 March 2022). "Moderna plots vaccines against 15 pathogens with future pandemic potential". Reuters. Archived from the original on 14 March 2022. Retrieved 15 March 2022.
  44. S2CID 229324351
    .
  45. PMID 33542081
    .
  46. ^ Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
  47. ^ Office of the Commissioner (18 December 2020). "Pfizer-BioNTech COVID-19 Vaccine". FDA. Archived from the original on 14 January 2021. Retrieved 21 December 2020.
  48. ^
    PMID 33316346
    .
  49. PMID 33619260
    .
  50. PMID 31323032
    .
  51. doi:10.1038/natrevmats.2017.56
    .
  52. ^
    PMID 23064118
    .
  53. PMID 33933145
    .
  54. ^ Goldman B (22 December 2020). "How do the new COVID-19 vaccines work?". Scope. Stanford Medicine. Archived from the original on 30 January 2021. Retrieved 28 January 2021.
  55. ^
    PMID 32916818
    .
  56. PMID 28101688
    .
  57. ^
    PMID 32047656
    .
  58. S2CID 38292712
    .
  59. PMID 21045153
    .
  60. ^ "Vaccine components". Immunisation Advisory Centre. 22 September 2016. Archived from the original on 26 January 2021. Retrieved 20 December 2020.
  61. PMID 17476302
    .
  62. PMID 21654214
    .
  63. S2CID 3278811
    .
  64. ^
    PMID 33593376
    .
  65. ^ a b c Cooney E (1 December 2020). "How nanotechnology helps mRNA Covid-19 vaccines work". Stat. Archived from the original on 1 December 2020. Retrieved 3 December 2020.
  66. PMID 27075952
    .
  67. ^ a b Cross R (6 March 2021). "Without these lipid shells, there would be no mRNA vaccines for COVID-19". Chemical & Engineering News. American Chemical Society. Archived from the original on 5 March 2021. Retrieved 6 March 2021.
  68. PMID 29489381
    .
  69. ^ Lowe D (3 February 2021). "Opinion: A straightforward explanation why more COVID-19 vaccines can't be produced with help from 'dozens' of companies". MarketWatch. Archived from the original on 5 February 2021. Retrieved 5 February 2021.
  70. ^ a b King A (23 March 2021). "Why manufacturing Covid vaccines at scale is hard". Chemistry World. Royal Society of Chemistry. Archived from the original on 24 March 2021. Retrieved 26 March 2021.
  71. ^ a b Sealy A (2 April 2021). "Manufacturing moonshot: How Pfizer makes its millions of Covid-19 vaccine doses". CNN. Archived from the original on 1 April 2021. Retrieved 3 April 2021.
  72. ^ a b c Weise E, Weintraub K (7 February 2021). "Race to the Vaccine: A COVID-19 vaccine life cycle: from DNA to doses". USA Today. Gannett. Archived from the original on 25 February 2021. Retrieved 24 February 2021.
  73. ^ Hopkins JS, Eastwood J, Moriarty D (3 March 2021). "mRNA Covid-19 Vaccines Are Fast to Make, but Hard to Scale". The Wall Street Journal. Archived from the original on 4 April 2021. Retrieved 3 April 2021.
  74. ^ Rowland C (18 February 2021). "Why grandparents can't find vaccines: Scarcity of niche biotech ingredients". The Washington Post. Archived from the original on 26 February 2021. Retrieved 7 March 2021.
  75. PMID 30832256
    .
  76. PMID 25419577
    .
  77. PMID 11112481
    .
  78. PMID 21987744
    .
  79. ^
    S2CID 227176634
    .
  80. ^ Neilson S, Dunn A, Bendix A (26 November 2020). "Moderna's groundbreaking coronavirus vaccine was designed in just 2 days". Business Insider. Archived from the original on 11 January 2021. Retrieved 28 November 2020.
  81. ^ Rabson M (27 February 2021). "From science to syringe: COVID-19 vaccines are miracles of science and supply chains". CTV News. Bell Media. Archived from the original on 27 February 2021. Retrieved 28 February 2021.
  82. PMID 21890902
    .
  83. PMID 27987145
    .
  84. S2CID 38532700
    .
  85. PMID 29275847
    .
  86. ^ "Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer. Archived from the original on 24 January 2021. Retrieved 17 December 2020.
  87. ^ a b Simmons-Duffin S. "Why Does Pfizer's COVID-19 Vaccine Need To Be Kept Colder Than Antarctica?". NPR.org. Archived from the original on 1 February 2021. Retrieved 18 November 2020.
  88. ^ a b "Fact Sheet for Healthcare Providers Administering Vaccine" (PDF). ModernaTX, Inc. Archived from the original on 28 January 2021. Retrieved 21 December 2020.
  89. ^ "Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures". NPR.org. Archived from the original on 16 November 2020. Retrieved 18 November 2020.
  90. New York Times. Archived
    from the original on 26 January 2021. Retrieved 21 November 2020.
  91. ^ Kuchler H (30 September 2020). "Pfizer boss warns on risk of fast-tracking vaccines". Financial Times. Archived from the original on 18 November 2020. Retrieved 21 November 2020.
  92. PMID 33243869
    .
  93. ^ a b Kwon D (25 November 2020). "The Promise of mRNA Vaccines". The Scientist. Archived from the original on 22 January 2021. Retrieved 27 November 2020.
  94. ^ Carmichael F, Goodman J (2 December 2020). "Vaccine rumours debunked: Microchips, 'altered DNA' and more" (Reality Check). BBC. Archived from the original on 13 March 2021. Retrieved 10 December 2020.
  95. PMID 25844274
    .
  96. ^
    S2CID 33489182
    .
  97. PMID 31547081
    .
  98. ^ a b "New crop of COVID-19 mRNA vaccines could be easier to store, cheaper to use". www.science.org. Archived from the original on 5 April 2022. Retrieved 6 April 2022.
  99. ^
    PMID 33093657
    .
  100. ^ Lowe D (1 March 2021). "A Malaria Vaccine Candidate". Science Translational Medicine. Archived from the original on 6 May 2021. Retrieved 7 May 2021.
  101. ^ Knapton, Sarah (20 September 2021). "First 'variant-proof' Covid vaccine starts trials in Manchester - Retired couple Andrew Clarke, 63, and his wife Helen, 64, from Bolton, became the first to receive the mRNA vaccine on Monday". The Daily Telegraph. Archived from the original on 20 September 2021. Retrieved 21 September 2021.
  102. ^ "Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer". PipelineReview. 20 September 2021. Archived from the original on 22 September 2021. Retrieved 21 September 2021.

Further reading

External links

Scholia has a profile for RNA vaccine (Q85795487).
Retrieved from "https://en.wikipedia.org/w/index.php?title=MRNA_vaccine&oldid=1171562730"